Full Text

Turn on search term navigation

1. Introduction

The arthritogenic alphaviruses that cause disease in humans include chikungunya virus (CHIKV), the Australian Ross River virus (RRV), the African o’nyong nyong virus (ONNV) and the South American Mayaro virus (MAYV) [1,2,3,4]. Symptomatic infection with these viruses results in a series of rheumatic manifestations that usually include acute fever, rash and myalgia and an acute, and often chronic, polyarthritis/polyarthralgia [4].

The largest outbreak of CHIKV-associated disease ever recorded began in 2004 and affected more than 100 countries (in Africa, Asia, Oceania, the Americas and Europe), with an estimated >10 million cases [5,6]. CHIKV disease also encompasses a spectrum of severe CHIKV disease manifestations resulting in hospitalizations (estimates range from 0.6% to 13% of cases) and mortality (estimates range from 0.024% to 0.7% of cases, primarily in the elderly) [5]. RRV causes a mean of ≈4600 cases per annum (2000–2015) in Australia where it is a notifiable disease [7], with a large outbreak (estimated at >60,000 cases) occurring in The Pacific Islands in 1979/80 [3,8]. In addition, recent outbreaks in the Shoalwater Bay Training Area in Australia (a major site of international military exercises) [9] highlighted the potential risk of international dissemination [10]. ONNV caused a large epidemic in 1959–1962 that started in northern Uganda and involved ≈2 million cases. A second epidemic was also reported in southern Uganda in 1996–7 [11]. However, subsequent case numbers have been low and sporadic [1,2], with malaria interventions against Anopheles species potentially also reducing ONNV transmission [12]. Nevertheless, ONNV morbidity in Africa is likely to be underestimated [12], and the risk of future outbreaks is considered high [13]. MAYV is largely restricted to South and Central America and the Caribbean, with about ≈30–100 cases per annum [1,2,4,13]. However, severe manifestations have been reported [14], and the emergence of recombinant MAYV strains represents a potential concern [15].

The large 2004–2019 CHIKV outbreak (and the potential severe disease manifestations) has resulted in the development of a series of vaccine candidates [5,16,17,18,19]. A CHIKV vaccine is deemed potentially [20] commercially viable [21], with the market size estimated at €500 million annually [5]. One CHIKV vaccine currently progressing into clinical trials is a recombinant poxvirus vaccine based on the multiplication-defective Sementis Copenhagen Vector (SCV) technology. The vaccine encodes the complete structural polyproteins of both CHIKV and Zika virus, and the vaccine is abbreviated as SCV-ZIKA/CHIK. The CHIKV polyprotein is used in many alphavirus vaccines [17,18,22,23,24] as self-assembled and matured viral surface glycoprotein spikes (comprising trimers of E1/E2 heterodimers) are believed to provide an authentically folded immunogen to the immune system [25,26,27]. One immunization with SCV-ZIKA/CHIK was previously shown to protect against viremia and disease after CHIKV challenge in an adult wild-type mouse model [16,28]. SCV-ZIKA/CHIK also induced neutralizing antibodies to CHIKV in non-human primates [29].

An RRV vaccine has been tested in a phase III trial and was well tolerated and immunogenic. This formalin and UV inactivated, whole virus RRV vaccine was alum-adjuvanted and delivered in three intramuscular 2.5 µg doses [22]. No further reports on development are publicly available, and the vaccine is currently owned by Ology Bioservices. Given the high cost of bringing a vaccine to the market [30] and the relatively low recognized case numbers for RRV, MAYV and ONNV, vaccines against these latter viruses are not likely to be deemed commercially viable.

The only commercial vaccine for an athritogenic alphavirus currently available is the formalin-inactivated, whole-virus Getah virus (GETV) vaccine that is sold by Nisseiken (Tokyo, Japan) as a mixed Japanese Encephalitis (JEV) and GETV vaccine [31]. This JEV/GETV vaccine is used in Japan to protect racehorses from GETV disease [31,32,33], which usually involves a 1–2 week-long, self-limiting disease characterized by fever, hind limb edema, lymph node swelling and a rash [34]. GETV has a broad geographical distribution that includes Asia, Europe and Australia [35] and was recently isolated from cattle in China [36]. RRV is also well known to infect horses [37,38], with some evidence for musculo-skeletal disease [39] and long-term poor performance [40].

Traditionally alphaviruses have been classified into antigenic complexes based on antibody cross-reactivity by hemagglutination inhibition, complement fixation and/or neutralization tests, with CHIKV, RRV, MAYV, ONNV and GETV all belonging to the Semliki Forest virus antigenic complex [41]. Consistent with this serogrouping, antibodies induced by infection with one of the aforementioned alphaviruses can often cross-react with other member(s) of this antigenic complex. For instance, (i) mouse convalescent RRV serum provided partial protection against CHIKV infection in wild-type mice [42], (ii) human convalescent CHIKV serum was able to cross-neutralize MAYV in vitro and in vivo, [43,44], (iii) CHIKV neutralizing monoclonal antibodies protected against ONNV in type I interferon-receptor-deficient mice and MAYV in wild-type mice [45] and (vi) MAYV-neutralizing monoclonal antibodies neutralized RRV and CHIKV in vitro [46]. An ensuing contention suggests that a vaccine for one of these alphaviruses might provide cross-protection against other viruses in the same antigenic complex [1,12,43,45]. In support, a live attenuated CHIKV vaccine was able to cross-protect against ONNV challenge in A129 mice [47], and the aforementioned RRV vaccine provided partial cross-protection against CHIKV in wild-type mice [48]. This contention perhaps finds support in the observations that cross-protection can be observed even for alphaviruses from different antigenic complexes [49,50,51]. However, the contention is not supported by the inconsistent cross-protection reported between relatively much more closely related CHIKV genotypes [52].

Using a newly identified human isolate of RRV from a transfusion case, RRVTT [53] characterized herein, and human isolates of CHIKV, ONNV and MAYV, we investigate the ability of infection with one alphavirus to mediate cross-protection against viremia in adult wild-type mice after subsequent infection with a heterologous alphavirus. Antibody-dependent cross-protection was also assessed by adoptive transfer of CHIKV convalescent sera into Rag1-/- mice persistently infected with the other three alphaviruses. Two contrasting vaccine modalities were also evaluated for their ability to mediate cross-protection; the live, multiplication defective, recombinant poxvirus SCV-ZIKA/CHIK [16,54] and the formalin-inactivated, whole-virus JEV/GETV vaccine [31,32,33]. Overall, our results argue that cross-protection, although clearly evident, is often suboptimal and unlikely to be of sufficient magnitude to be a realistic consideration in alphavirus vaccine development.

2. Materials and Methods 2.1. Ethics Statement All mouse work was conducted in accordance with the “Australian code for the care and use of animals for scientific purposes” as defined by the National Health and Medical Research Council of Australia. Mouse work was approved by the QIMR Berghofer Medical Research Institute animal ethics committee (P2235 A1606-618M), with CHIKV work conducted in a biosafety level-3 (PC3) facility at the QIMR Berghofer MRI (Australian Department of Agriculture, Water and the Environment certification Q2326 and Office of the Gene Technology Regulator certification 3445). 2.2. Mice, Infection, Virus Titration and Disease Evaluation

Female C57BL/6J mice (6–8 week) were purchased from Animal Resources Centre (Canning Vale, WA, Australia). All other mice strains were bred in-house at QIMR B. Interferon Response Factor 3 and 7 deficient (IRF3/7-/-) mice [55] were kindly provided by M.S. Diamond (Washington University School of Medicine, St. Louis, MO, USA). Rag1-/- mice are B and T cell-deficient on a C57BL/6 background; B6.129S7-Rag1tm1Mom/J (JAX). Rag2-/- mice are B, T and NK cell-deficient on a B6 background; B6-Rag2tm1Fwa Il2rgtm1Wjl (Taconic, Hudson, NY).

Mice were infected with 104 CCID50 of the indicated alphavirus subcutaneously (s.c.) into the top/side of each hind foot as described previously [42,56]. The procedure is illustrated in Figure S1. Serum viremia, tissue titers and foot swelling were determined as described previously [42,55,56,57]. Mice were monitored using a score card system that provided a score for joint swelling, posture perturbations, loss of activity, fur ruffling/shivering (indicative of pyrexia), hind leg weakness, injection site reaction (1 = mild, 2 = moderate, 3 = severe); mice reaching a score of 2 for any two disease manifestations or 3 in any 1 disease manifestation were humanely euthanized using carbon dioxide.

2.3. Cell Culture

The African green monkey kidney, Vero (ATCC#: CCL-81), and the baby hamster kidney, BHK-21 (ATCC# CCL-10), cell lines were maintained in RPMI 1640 (Thermo Fisher Scientific, Scoresby, VIC, Australia) supplemented with endotoxin-free [58] 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, Castle Hill, NSW, Australia) at 37 °C and 5% CO2. The Aedes albopictus mosquito-larva-derived cell line, C6/36 (ATCC# CRL-1660) was cultured in RPMI 1640 with 10% heat-inactivated FBS at 28 °C and 5% CO2.

2.4. The Arthritogenic Alphaviruses

RRV: RRVT48 has been described previously [59,60] (GenBank: GQ433359). RRVTT was isolated (using C6/36 cells) from a human blood donation sample implicated in a case of transfusion transmission [53] (GenBank: KY302801.1).

CHIKV: the CHIKV (isolate LR2006-OPY1; GenBank KT449801.1; DQ443544.2) was isolated from a traveller returning from Reunion Island [61] and was a kind gift from Dr. P. Roques (CEA, Fontenay-aux-Roses, France).

ONNV: The ONNV (isolate IMTSSA/2004/5163, GenBank: DQ383272, DQ383273 and DQ399055) was isolated from a 19-year-old French soldier in Chad [62]. An infectious clone was constructed by Dr. A. Merits (University of Tartu, Tartu, Estonia) [63]; ONNV virus was derived from this clone and was provided by Dr G. Pijlman (University of Wageningen, Wageningen, Holland). The virus was imported under Australian DAWR permit no. 0002142850 and was classified as a BSL2 (PC2) organism.

MAYV: The MAYV (isolate BeH407, GenBank: QDL88200.1) was isolated from a febrile patient from the Guama River outbreak in Brazil in 1955 [64]. The virus was a kind gift from Dr. M. Diamond (Washington University School of Medicine, St. Louis, Missouri, USA) and was imported as for ONNV.

GETV: GETVMM2021 was isolated in Malaysia from Culex gelidus in 1955 and was kindly provided by Dr. J. Aaskov of the WHO Collaborating Centre for Arbovirus Reference and Research, Queensland University of Technology, Brisbane, Australia and was re-sequenced to provide a full genome sequence (GenBank MN849355) and to confirm the identity of this isolate that was provided to the Reference Centre in the 1960s.

All the alphaviruses [65] and cell lines (MycoAlert, Lonza) tested negative for mycoplasma. All the alphaviruses, except ONNV, were propagated in C6/36 cells and were titered by CCID50 assays as described using C6/36 and Vero cells [42]. ONNV was propagated in BHK-21 cells and titered by CCID50 assays using BHK-21 cells. All medium and fetal calf serum were negative for endotoxin contamination using a highly sensitive macrophage reporter cell line [58]. In our experience, alphaviral preparations with even low levels of endotoxin contamination replicate poorly in wild- type mice. Viral expansion in the indicated cells is shown in Figure S2.

2.5. RRVTT Sequencing and Phylogenetic Tree Construction

RRVTT genome sequencing was performed as described previously [66]. Briefly, sequence-independent amplification was performed on viral RNA extracted from the isolate grown in C6/36 cells. A library was prepared from the amplified products and sequenced using a 316 chip on the Ion Torrent PGM platform, generating >500,000 reads. A consensus sequence was generated by performing an assembly with Geneious R8 software (Geneious, Auckland, NZ https://www.geneious.com) using RRV T48 (GenBank: GQ433359) as a reference. An alignment was performed with genome-length (and near-genome-length) RRV virus GenBank submissions using the MAFFT plugin of Geneious R8 with default parameters. A phylogenetic tree was constructed with the nucleotide sequence alignment in MEGA7 (Molecular Evolutionary Genetics Analysis version 7.0, Penn State University, Pennsylvania, USA) [67] using the Maximum Likelihood method and the General Time Reversible model with invariant sites (GTR + I) and 1000 bootstrap replicates. The tree was rooted using CHIKV as the out-group.

2.6. GETV MM2021 Sequencing C6/36 cells were infected with GETV at MOI 0.01 and incubated for 2 days, and culture supernatant was centrifuged at 3000 rpm for 15 min. PEG6000 (Sigma Aldrich, Darmstadt, Germany) was added to culture supernatant to a final concentration of 10%, incubated on a rotor overnight at 4 °C, and then centrifuged at 12,000 rpm for 1 h at 4 °C. The pellet was resuspended in RAV1 lysis buffer from the Nucleospin RNA virus kit (Machery-Nagel, Duren, Germany), and viral RNA was purified as per manufacturer instructions. RNA was sent to Australian Genome Research Facility (AGRF) for Next Generation Sequencing on the MiSeq platform (Illumina, California, USA), and 1,143,407 paired-end reads (150 bp) were generated. Reads were aligned to the GETV MI-110-C2 strain sequence (LC079087.1) using STAR Aligner and the consensus sequence was obtained using Integrative Genomics Viewer (IGV). A complete genomic sequence of the isolate was obtained (GenBank MN849355). Alignment analyses showed a > 99.69% nucleotide identity with the available partial sequence of MM2021 (GenBank AF339484). 2.7. Quantitative RT PCR of RRV Infected Feet

Quantitative RT-PCR (qRT-PCR) was performed using iTaq Universal SYBR® Green Supermix (Bio-Rad, California, USA) and RRV-specific NS3 primers: forward 5′-CCTGTYGAGGACGCCGATT-3′ and reverse 5′-CRTACCTACACAGACACGGAACTG-3′ (Thermo Fisher Scientific, Massachusetts, USA) with cycling conditions as described [68], with normalization to the housekeeping gene, RPL13A [69]. Each 20 μL reaction mix contained Supermix (10 μL; Bio-Rad, California, USA), RRV forward and reverse primer (0.3 µM), DNA template (2 μL) and nuclease-free water (6 μL; Sigma-Aldrich, Darmstadt, Germany). Reactions were run using the CFX 96 touch PCR detection system (Bio-Rad, California, USA) and data analyzed using Biorad CFX Real Time Analysis software.

2.8. Histology and Immunohistochemistry

Histology, immunohistochemistry and quantitation of stain were undertaken as previously described [42,55,57,70]. Briefly, feet were fixed in 10% formalin, decalcified with EDTA, embedded in paraffin and sections stained with hematoxylin and eosin (H & E; Sigma-Aldrich, Darmstadt, Germany). For immunohistochemistry, sections were stained with anti-CD3 (A0452; Dako, North Sydney, Australia) or anti-F4/80 (AB6640; Abcam, Melbourne, Australia), and detection used ImmPRESS-AP Anti-Rabbit IgG (alkaline phosphatase) Polymer Detection kit (Vector Laboratories, Burlingame, CA, USA) and Warp Red™ Chromogen Kit (Biocare Medical, Pacheco, CA, USA). Slides were scanned using Aperio AT Turbo (Aperio, Vista, CA USA) and analyzed using Aperio ImageScope software (Leica Biosystems, Mt Waverley, Australia) (v10) and the Positive Pixel Count v9 algorithm.

2.9. The Alphaviral Vaccines and Vaccination

The multiplication-defective, vaccinia-virus-based, Sementis Copenhagen Vector vaccine encoding the structural polyprotein cassettes of Zika virus and CHIKV (SCV-ZIKA/CHIK) and the control vaccine (SCV-Control) have been described previously [16,28,54] and were kindly provided by Sementis Ltd., Berwick, Australia. The CHIKV sequence was derived from strain 06-021 (GenBank: AM258992.1) obtained from a patient on La Reunion island in 2005 [71].

The formalin-inactivated whole virus JEV/GETV vaccine was purchased from Nisseiken Co. Ltd., Tokyo, Japan and was imported from NIID, Japan under Australian DAWR permit no. 0002721876, which restricted use to class 5 approved arrangement (AA) sites at QIMRB (quarantine facilities). The vaccine was developed using the MI-110 isolate (GenBank: LC079087.1) obtained from an infected horse during the 1978 GETV outbreak at the Miho training center, Ibaraki Prefecture, Japan [31].

The vaccines were administered intramuscularly (i.m.), with the dose split equally into both quadriceps muscles of restrained mice in 50 µL per muscle using an insulin syringe. 2.10. Antibody ELISA and Neutralization Assays

IgG responses were determined by standard ELISA using whole alphavirus as antigen and the mean plus 3 SD of naïve serum values as the endpoint as described [24]. Alphaviruses were purified from infected C6/36 cell supernatants by 40% polyethylene glycol precipitation (PEG6000) and ultracentrifugation (~134,000 rcf for 2 h at 4 °C) through a 20% sucrose cushion. Neutralization assays were performed essentially as described [24]. Heat-inactivated (56 °C, 30 min) mouse serum was incubated (in duplicate) with 150 CCID50 of alphavirus for an hour at 37 °C before adding to Vero cells (except for ONNV where BHK cells were used) (105 cells/well, 96-well plate). After 5 days, cells were fixed and stained with formaldehyde and crystal violet and the 50% neutralizing titers interpolated from optical density (OD) versus dilution plots.

2.11. E1/E2 Contact Residue Visualizations

The figures were generated using Pymol Molecular Graphics System (version 2.3.3) (Schrodinger, NY, USA) using the structure described in Song et al. 2019 [72] (PDB: 6JO8).

2.12. Serum, IgM and Ribavirin Treatments of Rag-/- Mice Anti-CHIKV convalescent serum was collected from 18 mice infected 3–4 weeks previously with CHIKV. The serum was pooled and 200 µL injected intraperitoneally (i.p.) into persistently infected Rag1-/- mice.

Rag2-/- mice persistently infected with RRVTT were treated (i) with an anti-RRV purified IgM monoclonal antibody, 37B2 [73], a control antibody 3G1.1 [74] (400 µg) or PBS (i.p. 400 µL) or (ii) with ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) (Sigma-Aldrich, Darmstadt, Germany) (i.p. 100 mg/kg) or diluent (PBS 100 µL) for five consecutive days. Viremia levels were determined as described above.

2.13. Statistics Statistical analyses of experimental data were performed using IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA). The t-test was used when the difference in variances was <4, skewness was >2 and kurtosis was <2. Otherwise, the non-parametric Kolmogorov–Smirnov test was used. Correlation analyses used the non-parametric Spearman’s rank-order correlation. 3. Results 3.1. Characterisation of RRVTT, a Contemporary Human Isolate from an RRV Disease Patient, in Wild-Type Mice

The RRVT48 strain has been extensively used in mouse models of RRV musculoskeletal disease [75,76,77]. RRVT48 is a mosquito-derived, mouse-adapted isolate, with a largely undocumented passage history [60]. A contemporary clinical RRV isolate was recently obtained from a transfusion case, where the donor had both symptoms of RRV (fatigue and arthralgia) and tested positive for RRV by serology [53]. We sequenced this isolate (RRVTT; GenBank accession number: KY302801) with phylogenetic analyses illustrating that it clustered with another human isolate (98% nucleotide identity) but was relatively distant from RRVT48 (96% nucleotide identity) (Figure S3a), with both conservative and non-conservative amino acid differences in structural and non-structural proteins evident between RRVT48 and RRVTT (Figure S3b,c). Nevertheless, the binding of a small panel of monoclonal antibodies was the same (Figure S3d), and in vitro replication was largely comparable, (Figure S3e) for these two virus isolates.

To the best of our knowledge, no human RRV isolate has been tested for its ability to infect and cause disease in mice. Adult (6–10 week old) female C57BL/6J mice were thus infected s.c. in the hind feet with RRVT48 or RRVTT at a dose of 104 CCID50. Viremia was significantly higher for RRVT48-infected mice compared with RRVTT (Figure 1a, days 1–3), with the age of the mice (6- versus 24-week-old) not having a significant effect on peak viremia (Figure 1a, inset bar graph). Both the viral titers on days 2 and 6 (Figure 1b) and viral RNA levels on days 6 and 30 post-infection (Figure 1c) in the feet were not significantly different for the two RRV isolates. Foot swelling was, however, significantly higher for RRVTT, although it only reached a maximum mean increase of≈12% (Figure 1d), substantially lower than the >60% increase seen in the adult wild-type mouse model of CHIKV arthritis [42,75], perhaps consistent with the substantially lower overall pathogenicity of RRV when compared with CHIKV in humans [4]. The RRVTT- associated swelling, although evident in 6-week-old mice, was absent in 24-week-old mice (Figure 1d, inset bar graph). Age dependence for alphavirus mouse models is well described [78], with the traditional RRVT48 mouse model using 3-week-old weanling mice so that an overt musculoskeletal phenotype can be observed [75].

H&E staining of arthritic feet from 6-weeks-old RRV-infected mice day 6 post-infection illustrated the characteristic mononuclear cellular infiltrates [4,79] that were clearly evident in muscle tissues (Figure 1e, black ovals), with some also evident around joint tissues (Figure 1f, black ovals). Quantitation using blue (nuclear)/red (cytoplasmic) staining ratios showed that cellular infiltrates were not significantly different for RRVT48 and RRVTT (Figure 1g). (Leukocytes tend to have higher nuclear to cytoplasm ratios than resident cells, so blue/red ratios represents a measure of leucocyte infiltration [56]). Subcutaneous edema was, however, more evident in RRVTT-infected mice (Figure 1h, edema indicated by asterisks), perhaps explaining the foot swelling differences seen in Figure 1d.

CD4+ CD3+ T cells and monocytes/macrophages are intimately associated with alphaviral arthritides [5,80]. Immunohistochemistry (IHC) for anti-CD3 on day 6 post-infection illustrated that infiltrating CD3+ T cells were often found in muscle tissues (Figure 1i, black ovals). RRVTT arthritis was associated with more infiltrating CD3+ T cells when compared with RRVT48 arthritis (Figure 1j). F4/80+ monocytes/macrophages were often found in subcutaneous connective tissues (Figure 1k) and were not significantly different for the two RRV strains (Figure 1l). Thus, both RRVTT and RRVT48 infections of adult wild-type mice show the inflammatory infiltrates characteristic of alphaviral arthritides [4].

RRVTT therefore represents a contemporary (non-mouse-adapted) human isolate of RRV that is suitable for comparison, in adult wild-type mouse models, with other (non-mouse-adapted) human arthritogenic alphavirus isolates. 3.2. Protection and Cross-Protection Mediated by Arthritogenic Alphaviruses Infection

Antibody responses directed at E1 and/or E2 proteins are believed to be the primary mediators of protection against arthritogenic alphaviruses [72,81], although other factors may play a minor role [56,82]. The phylogenetic relationships between the E1/E2 amino acid sequences for alphaviruses used herein are shown in Figure 2a.

Using the new human RRVTT isolate and human isolates of CHIKV, ONNV and MAYV (Figure 2a), adult C57BL/6J mice were infected with one alphavirus and were then challenged with the same (homologous) or different (heterologous) alphavirus (Figure 2b). As expected, in all four homologous combinations, complete protection against viremia was observed (Figure S4a,d, middle top graphs, red lines). Complete protection is defined herein as no post-challenge viremia detected on any day in any mouse; (limit of detection 2 log10CCID50/mL of serum).

As might also be expected amongst members of the same antigenic complex [41], in all heterologous combinations, some level of significant cross-protection was always evident (Figure 2c, see p-values). However, for half of the heterologous combinations, cross-protection was partial (Figure 2c, middle column of graphs and third row of graphs). Thus, although all these viruses are clearly antigenically related, complete cross-protection was not universally assured. MAYV infection completely protected against delectable RRVTT viremia, whereas RRVTT infection only partially cross-protected against MAYV viremia (Figure 2c). Although this might be interpreted as some form of one-way cross-protection [83], it should be noted that the “immunizing” viremias were (at their peak) ~100-fold higher for MAYV than for RRVTT (Figure S4).

3.3. Conservation of Receptor Contact Residues in E1 and E2

Although antibody-based virus neutralization can involve a range of mechanisms [5,46,85], most neutralizing antibodies target E1/E2, and many block receptor binding [81]. The 48 contact residues between the arthritogenic alphavirus receptor, MXRA8, and the E1/E2 heterotrimeric envelope glyoproteins of CHIKV were recently identified by cryo-electron microscopy [72]. These residues are relatively well conserved between CHIKV and ONNV (77% amino acid identity) but are less well conserved between CHIKV and MAYV (60% amino acid identity) and CHIKV and RRV (48% amino acid identity) (Figure 3a,b). The contact residues are represented on cryo-electron microscopy images, with color-coding (as in Figure 3a) illustrating the levels of conservation (Figure 3b).

Convalescent CHIKV, ONNV, MAYV and RRVTT sera from individual mice were used to determine the neutralization and cross-neutralization titers against CHIKV. When these titers were plotted against the percentage of amino acid identity in the E1/E2 receptor-binding residues, a highly significant relationship became evident (Figure 3c, left graph). Both the significance (p-value) and the correlation coefficient (rho) were lower when the same analysis was undertaken using the percentage of amino acid identity for all of the amino acids in E1/E2 (Figure 3c, middle graph), or the percentage of amino acid identity for all of the amino acids encoded by the viral genomes (Figure 3c, right graph). The level of cross-protection mediated by a polyclonal antibody response would thus appear to be closely related to the level of conservation in the E1/E2 receptor-binding residues.

Another key observation here is that reductions in the percentage of amino acid identities resulted in large drops in cross-neutralization titers. For example, an approximate halving of the percentage amino acid identity from 100% to 48% resulted in a ~100 fold drop in cross-neutralization titers (Figure 3c, left graph), likely explaining why only partial cross-protection was frequently observed in Figure 2c.

3.4. Cross-Protection Provided by SCV-ZIKA/CHIK Vaccination in Wild-Type Mice

We have previously shown that a single vaccination of adult female C57BL/6J mice with 106 pfu of the SCV-ZIKA/CHIK vaccine i.m. induced CHIKV-specific ELISA and neutralizing antibody responses and provided complete protection against CHIKV viremia after CHIKV challenge [16]. To determine whether such SCV-ZIKA/CHIK vaccination could provide cross-protection against other human arthritogenic alphaviruses in the same antigenic complex, C57BL/6J mice were vaccinated with 106 pfu SCV-ZIKA/CHIK, and antibody responses and protection against ONNV, RRVTT and MAYV infection were determined (Figure 4a). Vaccination with 106 pfu of SCV-ZIKA/CHIK generated ELISA and neutralizing responses specific for both CHIKV and ONNV, although ELISA responses were slightly lower (1.6 fold) (Figure 4b), and neutralization titers were ~10-fold lower for ONNV when compared with CHIKV (Figure 4c). Nevertheless, the mean cross-neutralization titer against ONNV of 40.2 + SE 9.6 (Figure 4c) was sufficient for complete cross-protection against detectable viremia post-ONNV challenge in this model (Figure 4d, red arrow). Although SCV-ZIKA/CHIK vaccination did induce a mean reciprocal endpoint anti-MAYV ELISA titer of 111 + SE 30 (Figure 4e), no cross-neutralization titers were detected (Figure 4f), and no cross-protection was observed (Figure 4g). No cross-reactive (Figure 4h) or cross-neutralizing (Figure 4i) antibody responses against RRVTT were observed, and a single vaccination with 106 pfu of SCV-ZIKA/CHIK was unable to provide any cross-protection against viremia (Figure 4j).

To determine whether increased SCV-ZIKA/CHIK vaccination dose and/or boosting might provide cross-protection against RRVTT, mice were vaccinated twice with 106 pfu SCV-ZIKA/CHIK, once with 107 pfu SCV-ZIKA/CHIK (Figure S5) or twice with 107 pfu SCV-ZIKA/CHIK (Figure 4k). Only the latter dose and schedule induced RRV-specific antibody responses detectable by ELISA, although mean levels were ~15-fold lower than CHIKV-specific ELISA titers (Figure 4l, p = 0.005). No cross-neutralizing antibody responses were detected against RRVTT (Figure 4m); nevertheless, partial cross-protection against RRVTT viremia after RRVTT challenge was evident (Figure 4n), with 3 out of 6 mice showing no detectable viremias. Thus even when SCV-ZIKA/CHIK was given at a 10-fold higher dose and twice, only 50% of the mice were fully protected against a detectable RRVTT viremia.

3.5. Cross-Protection Against RRVTT Mediated by the JEV/GETV Vaccine in Wild-Type Mice

Of the arthritogenic alphaviruses described herein, GETV is the most closely related to RRV (Figure 3a). A formalin-inactivated JEV/GETV vaccine is available in Japan for use in horses (Nisseiken, Tokyo, Japan) [31,32,33] and currently represents the only arthritogenic alphavirus for which a vaccine is commercially available. RRV also infects horses [37,38], but no commercial RRV vaccine is currently available for veterinary or human use.

We determined that the JEV/GETV vaccine contains 172 µg/mL of protein using a standard Bradford protein assay. The equine 3 mL dose thus represents ~500 µg of protein, with two i.m. doses separated by 1 month recommended for horses by the manufacturer. To explore whether the JEV/GETV vaccine could provide cross-protection against RRV, mice were vaccinated once i.m. with 10 µg of the JEV/GETV vaccine (Figure 5a); assuming 50% of this vaccine is GETV, this represents a vaccination dose of ~5 µg of GETV proteins. An experimental formalin-inactivated RRV vaccine at a single dose of 2.5 µg was previously shown to induce mean reciprocal neutralizing titers of ~30 and provided protection against viremia in 93% of CD-1 mice [48]. Reciprocal 50% neutralizing antibody titers for RRV of >10 were deemed a conservative estimate of protection in a human vaccine trial [22].

Mice vaccinated once with 10 µg of JEV/GETV vaccine generated a mean reciprocal anti-GETV ELISA antibody titer of 4141 + 1365, with the mean reciprocal anti-RRVTT ELISA titers ~100 fold lower at 37.7 + SE 23.1 (Figure 5b). The mean reciprocal anti-GETV neutralizing titer was 35 + SE 20, with anti-RRVTT cross-neutralizing titers below the limit of detection (Figure 5c). PBS vaccination induced no detectable antibody responses (Figure 5b,c). JEV/GETV vaccination at this dose produced no detectable protection against RRVTT challenge (Figure 5d). Mice vaccinated twice with 20 µg of JEV/GETV vaccine (Figure 5e) generated a mean reciprocal anti-GETV ELISA antibody titer of 2578 + SE 854, with the mean anti-RRVTT ELISA titers 14-fold lower at 179 + SE 41 (Figure 5f). The mean reciprocal anti-GETV neutralizing titer was 38.7 + SE 16, and the anti-RRVTT cross-neutralizing titers were again below detection (Figure 5g). The increased dose and second vaccination (Figure 5a vs. Figure 5e) thus provided no significant increase in anti-GETV responses (Figure 6b vs. Figure 6f and Figure 6c vs. Figure 6g) or anti-RRVTT neutralizing antibody responses (Figure 5c vs. Figure 5g) but did increase anti-RRV ELISA titers approximately 5-fold (Figure 5f vs. Figure 5b; 179/37.7 = 4.75). Following challenge with RRVTT, significant, but only partial, protection against viremia was observed (Figure 5h). (As we do not as yet have a mouse model of GETV, we were unable to verify that the commercial JEV/GETV vaccine can protect against GETV in mice.)

The E1/E2 receptor binding residues are relatively well conserved for both RRVTT and GETVMI-110 (the vaccine strain), and RRVTT and GETVMM2021 (the GETV isolate used for the ELISA and neutralization assays) (Figure 5i). Given the 75% amino acid identity between RRVTT and GETVMI-110 (Figure 5i), the poor level of cross-protection (Figure 5d,h) might be viewed as somewhat unexpected. However, the JEV/GETV vaccine is formalin-fixed, a process known to reduce immunogenicity [87], potentially by altering the antigenic structure [88]. Formalin irreversibly modifies certain epitopes, particularly those containing lysine (K) and (to a lesser extent) tryptophan (W) residues [89]. Induction of cross-reactive antibodies that are reliant on conserved epitopes that (for instance) contain E1 K130 and/or W89 (Figure 5i, underlined) may thus be compromised.

3.6. Cross-Protection Against RRVTT after SCV-ZIKA/CHIK Vaccination in IRF3/7-/- Mice

Mice defective in type I interferon (IFN) responses, such as IFN alpha-receptor-deficient (IFNAR-/- or A129) mice, have been widely utilized to evaluate alphaviral vaccines and antibodies, with protection against mortality often used as an indicator of efficacy [45,52,90,91,92]. Such mice have also been used to demonstrate cross-protection against ONNV by a CHIKV vaccine [47]. Herein we used Interferon Response Factor 3- and 7-deficient (IRF3/7-/-) mice rather than IFNAR-/- mice, as severe disease has a slower onset [55], which facilitates compliance with ethically defined endpoints for euthanasia, as monitoring of animal well-being can be reduced to twice daily. The behavior of CHIKV in IRF3/7-/- and IFNAR-/- mice is otherwise very similar; both IFNAR-/- and IRF3/7-/- mice are unable to mount protective type I IFN responses and generally show a lethal phenotype associated with hemorrhagic shock after CHIKV infection [55,93]. The latter represents a severe disease manifestation occasionally seen in CHIKV and MAYV patients [5]. To our knowledge, RRV infection of IRF3/7-/- mice has not previously been reported, with infection (as might be expected [55]) resulting in high viremia, foot swelling (edema) and mortality (Figure S6a–d). Subcutaneous monocyte/macrophage infiltration was also illustrated by immunohistochemistry (Figure S6e); a feature not previously reported for alphavirus infections in type I IFN response defective mice.

To evaluate cross-protection in type I interferon-response-deficient mice, IRF3/7-/- mice were vaccinated once with 106 pfu SCV-ZIKA/CHIK and were then challenged with RRVTT (Figure 6a). Vaccination induced CHIKV-specific ELISA and neutralizing antibody responses, but anti-RRVTT antibody responses were below the level of detection (Figure 6b,c). After RRVTT challenge, both SCV-ZIKA/CHIK and SCV-control vaccinated mice developed high viremias; although on days 4 and 5, post-challenge SCV-ZIKA/CHIK-vaccinated mice showed significant 0.8-1.4 log lower viremia titers (Figure 6d). After RRVTT challenge, both SCV-ZIKA/CHIK and SCV-control vaccinated mice showed similar levels of foot swelling (Figure 6e); images of typical foot swelling in control mice are shown in Figure 6f. Mice were also monitored for a series of disease signs (1 = mild, 2 = moderate, 3 = severe); any animal scoring 2 in two or more disease parameters (or 3 in any one parameter) was deemed to have reached an ethically defined endpoint requiring euthanasia. No SCV-ZIKA/CHIK-vaccinated animals reached this criterion, whereas all SCV-control vaccinated mice scored 2 for Joint swelling and 2 for Posture on day 6 and were euthanized (Figure 6g). Presented as a Kaplan–Meier survival plot, SCV-ZIKA/CHIK vaccinated animals showed significantly better survival than SCV-control vaccinated mice (Figure 6h).

SCV-ZIKA/CHIK vaccination of IRF3/7-/- mice thus provided no cross-protection against RRVTT foot swelling, marginal cross-protection against viremia and disease, but complete cross-protection against mortality. The same vaccination also provided no protection against RRVTT viremia in wild-type mice (Figure 4j). Survival in the type I interferon-deficient mouse model is thus a poor indicator of (or poor surrogate marker for) cross-protection against infection and arthritic disease, with low-level cross-reactive anamnestic responses perhaps only just able to generate sufficient immune responses in time to prevent mortality.

3.7. Serological Protection and Cross-Protection Evaluated in Rag-/- Mice

Anti-alphaviral IgG responses are well described as mediators of protection [5,7,46,81], with T cells perhaps playing a minor role [56,82]. The alphavirus cross-protection literature has traditionally implicated T cells [51,94,95,96,97,98], although antibody responses have also been implicated [42,50] and cross-reactive and cross-neutralizing antibodies are well described [43,44,45,99].

Rag-/- mice have no B or T cell responses and are unable to clear CHIKV or RRV infections resulting in long-term steady-state viremias [56,82]. Rag1-/- mice were infected with CHIKV, ONNV, MAYV or RRVTT (n = 4 per group), and after the persistent viremias were established, mice were treated on day 10 with pooled CHIKV convalescent sera (Figure 7a). The sera were pooled from 18 CHIKV-infected mice and had a reciprocal CHIKV IgG ELISA endpoint titer of ~50,000. With the exception of RRVTT, all viremia levels dropped to levels below detection within a day, with the MAYV viremia reappearing by day 20 in three mice and by day 30 in the remaining mouse (Figure 7b; Figure S7). The ONNV and CHIKV viremia levels remained depressed for >47 days and were not significantly different from each other (on days 34 and 39) (Figure 7b). The results are consistent with the ability of SCV-ZIKA/CHIK vaccination to protect against CHIKV [16] and cross-protect against ONNV, but not MAYV or RRV (Figure 4). This pattern (Figure 7b) also correlates well with amino acid identity in receptor contact residues [81] shown in Figure 3b (Figure S7); with the cross-protection activity of anti-CHIKV sera against persistent viremia, best for ONNV (77% identity), less for MAYV (60% identity) and least for RRVTT (48% identity) (Figure 7b). Taken together, these data implicate cross-neutralizing IgG responses as playing an important role in mediating cross-protection. (These data also illustrate the utility of Rag-/- mice for evaluating anti-viral treatments for arthritogenic alphaviruses, with further examples shown in Figure S9.)

4. Discussion

We illustrate herein that some level of cross-protection, mediated by CHIKV, ONNV, MAYV and RRV infections, was universal in adult wild-type mice, as might be envisaged given these viruses all belong to the Semliki Forest virus antigenic complex. However, in half the combinations, cross-protection was only partial (Figure 2c, Figure S4). The live attenuated recombinant poxvirus-based SCV-ZIKA/CHIK vaccine was able to mediate complete cross-protection against ONNV challenge but was unable to provide such protection against MAYV or RRV (Figure 4). The formalin-inactivated JEV/GETV vaccine was unable to provide complete cross-protection against RRV challenge, despite the high E1/E2 sequence identities between these two viruses (Figure 2a and Figure 5i). Both infection-mediated and vaccine-mediated cross-protection were thus often partial or absent.

Although SCV-ZIKA/CHIK vaccination provided effective cross-protection against ONNV challenge (Figure 4d), the mean neutralizing antibody response was ~10-fold lower for ONNV than for CHIKV (Figure 4c). In addition, after SCV-ZIKA/CHIK vaccination, the ratio of neutralizing titers over ELISA titers was significantly lower for ONNV than for CHIKV (Figure S8a, p < 0.001), further illustrating that the SCV-ZIKA/CHIK vaccine is less ideal for ONNV than it is for CHIKV. In humans, the minimum vaccine dose to achieve protection against its designated target is generally used to avoid excessive side effects such as reactogenicity [100] and to reduce the cost of goods. In humans, reciprocal neutralization titers of >10 have been deemed to represent a conservative estimate of the protective titer for RRV [22] and for CHIKV [101,102]; a contention not inconsistent with the mouse data presented herein (Figure S8b). Thus, if the SCV-ZIKA/CHIK vaccine dose was reduced in humans to provide such levels of anti-CHIKV neutralization, the lower cross-neutralization titers against ONNV may provide suboptimal cross-protection against ONNV. Testing in clinical trials and ultimate licensing of a vaccine that requires higher or more vaccine doses in order to also provide cross-protection might present regulatory hurdles when the technology (if not the market) likely exists to generate an appropriately targeted vaccine. Vaccine manufacturers are also likely to focus on the primary target and not complicate registration and licensing by risking increased side effects (and countenancing increased cost of goods) in an attempt to capture an additional, economically less viable, cross-protection market.

Despite the high level of sequence identity between GETV and RRV, JEV/GETV vaccination was unable to induce anti-RRV cross-neutralizing antibody responses (Figure 5c,g) or to provide complete protection against RRVTT challenge (Figure 5d,h). Anti-RRVTT ELISA responses were also 100- and 14-fold lower than the anti-GETV ELISA titers (Figure 5b,f, respectively), again suggesting that cross-protection against RRV would require a higher dose of the JEV/GETV vaccine than that needed for protection against GETV. Even the anti-GETV neutralizing responses generated by the GETV vaccine were relatively poor, perhaps suggesting that a very high dose or multiple vaccinations would be needed before cross-neutralizing responses to RRV are seen. The suboptimal induction of neutralizing antibody responses by a formalin-fixed vaccine [87,88,89] is perhaps supported herein by the observation that the ratios of neutralizing titers over ELISA titers were significantly higher for SCV-ZIKA/CHIK than for JEV/GETV vaccinations (Supplementary Figure S8c, p < 0.0001). Generating cross-neutralizing responses with a formalin-fixed vaccine may thus represent a particularly difficult hurdle.

Herein, protection against viremia was used as the readout, rather than protection against disease, which primarily manifests in humans as acute and often chronic polyarthralgia/polyarthritis [4,5]. After injection of 104 CCID50 of CHIKV s.c. into the foot of adult wild-type mice, the arthritic foot swelling reached a maximum mean ~60%–80% increase in foot height x width [56,103]. For RRVTT, such foot swelling only reached ~12% in 6-week-old mice and was essentially below detection in 24-week-old mice (Figure 1d). Although a higher dose (105 or 106 PFU) and different strain of MAYV (BeH407) has been reported to induce foot swelling comparable to that seen for CHIKV after s.c. injection into the feet [104], no significant foot swelling was seen herein in control mice challenged with 104 CCID50 MAYV (or ONNV). These alphaviruses thus show distinct differences in their propensity to induce foot swelling in these wild-type mouse models, making cross-protection against arthritis difficult to standardize. No mouse models have so far been developed that measure polyarthralgia. The adult wild-type CHIKV mouse model recapitulates many aspects of human disease [42,57], with recent RNA-Seq comparisons further illustrating that this mouse model shares many inflammatory processes with those seen in humans [105,106]. However, such comparisons are not yet available for ONNV, MAYV or RRV. Further development and characterization of alphavirus mouse models would thus be required before one could formally test the inherent assumption herein that suppression of viremia correlates with suppression of rheumatic disease.

Overall the data presented herein does not support the concept of effective mediation of cross-protection by arthritogenic alphavirus vaccines. A vaccine capable of protecting against multiple arthritogenic alphaviruses would likely require a polyvalent vaccine [54] or a mixture of individual vaccines, as was recently described for the three major encephalitic alphaviruses [107]. However, the current small market size and low mortality rates for RRV, ONNV and MAYV would likely make such endeavors commercially unattractive. New outbreaks may clearly change this contention [10,14]; until then, mosquito control measures are likely to remain at the forefront of public health measures against these latter alphaviruses [108].

5. Conclusions A CHIKV vaccine is deemed commercially viable, and several vaccine candidates are progressing into, and through, human clinical trials. Although CHIKV-vaccine or CHIKV-infection provided a level of cross-protection against infection by ONNV, MAYV and RRV, cross-protection and/or cross-neutralizing antibody responses were significantly lower than protection and/or neutralizing antibody responses against CHIKV. Increasing CHIKV vaccine dosing and/or scheduling to try and capture the much smaller cross-protection markets is unlikely to be attractive to regulators or vaccine manufacturers.

Figure 1. Ross River viruses (RRVs) RRVTT and RRVT48 arthritis in adult wild-type mice. (a) Viremia in adult C57BL/6J female mice (6- and 24-weeks-old) infected with 4 log10CCID50 of RRVTT or RRVT48. RRVT48 viremia was significantly higher on days 1, 2 and 3 (p < 0.001); statistics by Kolmogorov-Smirnov tests (n = 6-12 mice per time point and data were derived from 3 independent experiments). Bar graph insert shows mean peak viremias for mice infected at 6 or 24 weeks of age; (b) Viral titers in feet of C57BL/6J mice infected as in (a) (n = 6 feet from 3 mice per time point); (c) Quantitative RT-PCR of feet from RRV infected mice (taken days 6 and 30 post-infection) using RRV NS3 primers normalized to RPL13a (n = 3 feet from 3 mice per group). Naïve represents uninfected mice; (d) Percentage increase in foot height x width (relative to day 0) for 6-week-old mice infected as in (a), with n = 12 feet from 6 mice per group per time point. Inserted bar graph shows the mean peak foot swelling on day 6 post-infection for mice aged 6 weeks (n = 12 feet from 6 mice) or 24 weeks (n = 6 feet from 3 mice) at time of infection. Differences between strains only reached significance on day 6 (see inserted bar graph; t-test); (e) H&E staining of muscle tissues in foot sections from 6-week-old C57BL/6J female mice infected as in (a). Black ovals indicate some of the areas containing inflammatory infiltrates. (*); (f) H&E staining as in (e) showing inflammatory infiltrates near joint tissues; M = muscle; SS = synovial space; (g) Ratio of nuclear (blue/dark purple) to non-nuclear (red) staining of H&E stained foot sections (a measure of leukocyte infiltration). Data from 4-6 feet from 3-4 mice per group, with 2-3 sections scanned per foot and values averaged to produce one value for each foot. Statistics by Kolmogorov-Smirnov tests (as difference in variance were 112 and 26, respectively); (h) H&E staining as in (e) showing areas of subcutaneous edema (*); (i) Immunohistochemical (IHC) staining of sections described in (e), with anti-CD3 antibody (primarily T cells) showing positive staining cells in muscle tissues (examples indicated with black ovals); (j) Aperio Positive Pixel Count Determination of anti-CD3 staining; strong positive red pixels per µm2 in whole foot sections (n = 6-12 feet per sample, with 3 sections per foot). Statistics by Kolmogorov-Smirnov tests (as difference in variance were 225 and 3281, respectively); (k) IHC staining using anti-F4/80 (monocytes/macrophages) of section described in (h), illustrating positive cells in subcutaneous tissues (the epidermis is indicated); (l) As for (j) except for anti-F4/80 staining. Statistics by Kolmogorov-Smirnov tests (as difference in variance were 70 and 142, respectively).

Figure 2. Cross-protection by infection. (a) Phylogenetic trees of E1/E2 amino acid sequences (as in Supplementary Figure S3a of arthritogenic alphaviruses used herein, with Southern Elephant Seal virus (SESV) [84] used as an outgroup; (b) Timeline of infection, challenge and viremia determinations; (c) Heterologous cross-protection. Black lines represent mock-infected or naïve mice challenged with the indicated virus; red lines represent viremia after infection and heterologous challenge. Numbers in brackets represent mouse numbers. Statistics by Kolmogorov-Smirnov tests taking Mock (white fill) and Naïve (black fill) together, and comparing with heterologous challenge group (red).

Figure 3. Conservation of receptor contact residues amongst the arthritogenic alphaviruses. (a) The 48 residues on the E1/E2 Chikungunya virus (CHIKV) viral spike glycoproteins reported to make contact with the arthritogenic alphavirus receptor, MXRA8 [72] are aligned against the corresponding residues in o'nyong nyong virus (ONNV), Mayaro virus (MAYV) and RRV. Conservative and non-conservative substitutions are defined as described [86]. The complete sequence for ONNV IMTSSA 2004 was not available so residues E1 39-84 and E2 18-123 were derived from the closely related ONNV SG650 [62]; (b) The crystal structure of CHIKV E1/E2, with the receptor contact residues colored as in (a) for each of the indicated alphaviruses. Percentages indicate the percentage of identical contact residues relative to CHIKV; (c) Wild-type C57BL/6J mice were infected with CHIKV, ONNV MAYV or RRV. After 5 weeks, sera from each mouse was tested for its CHIKV neutralization titer. The neutralization titers were plotted against the % identity in E1/E2 receptor binding amino acids (left), the % identity in E1/E2 amino acids (middle) and % amino acid identity in the total genome (right). Statistics by Spearman's correlations, p and rho indicated.

Figure 4. Cross-protection mediated by Sementis Copenhagen Vector (SCV)-ZIKA/CHIK vaccinations in wild-type mice. (a) Timeline of vaccination with a single dose of 106 pfu of SCV vaccines, antibody response determinations and challenge; (b) CHIKV and ONNV endpoint IgG ELISA titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control (limit of detection 1 in 30); (c) CHIKV and ONNV 50% neutralization titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control (limit of detection 1 in 10); (d) ONNV viremia post-challenge with ONNV in mice vaccinated with SCV-ZIKA/CHIK or SCV-Control or PBS (n = 6 mice per group). (Limit of detection for each mouse 2 log10CCID50/mL of serum.); (e) CHIKV and MAYV endpoint IgG ELISA titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control; (f) CHIKV and MAYV 50% neutralization titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control; (g) MAYV viremia post-challenge with MAYV in mice vaccinated with SCV-ZIKA/CHIK or SCV-Control or PBS (n = 6 mice per group); (h) CHIKV and RRV endpoint IgG ELISA titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control; (i) CHIKV and RRVTT 50% neutralization titers four weeks post-vaccination with SCV-ZIKA/CHIK or SCV-Control; (j) RRVTT viremia post-challenge with RRVTT in mice vaccinated with SCV-ZIKA/CHIK or SCV-Control (n = 6 mice per group); (k) Timeline of 2 vaccinations with 107 pfu of SCV vaccines, antibody response determinations and RRVTT challenge; (l) CHIKV and RRV endpoint IgG ELISA titers after 2 vaccinations with SCV-ZIKA/CHIK or SCV-Control; (m) CHIKV and RRVTT 50% neutralization titers after 2 vaccinations with SCV-ZIKA/CHIK or SCV-Control; (n) RRVTT viremia post-challenge with RRVTT in mice vaccinated twice with SCV-ZIKA/CHIK or SCV-Control or PBS (n = 6 mice per group). Viremias were not significantly different for any individual day; taking all viremia data for days 1-4 together (n = 24 per group), the SCV-ZIKA/CHIK vaccinated mice had a significantly lower viremia than the SCV-Control vaccinated mice (p < 0.001, Kolmogorov-Smirnov test).

Figure 5. Cross-protection against RRV mediated by the Japanese Encephalitis (JEV)/ Getah virus (GETV) vaccine. (a) Timeline of the single 10 µg vaccination with JEV/GETV vaccine (the GETV vaccine strain is MI-110) or PBS, antibody measurements and RRVTT challenge; (b) GETVMM2021 and RRVTT endpoint IgG ELISA titers after 1 vaccination with JEV/GETV vaccine or PBS (limit of detection 1 in 30); (c) GETVMM2021 and RRVTT 50% neutralization titers after 1 vaccination with JEV/GETV vaccine or PBS (limit of detection 1 in 10); (d) RRVTT viremia post-challenge with RRVTT in mice vaccinated once with JEV/GETV vaccine or PBS (n = 6 mice per group). (Limit of detection for each mouse 2 log10CCID50/mL.); (e) Timeline of two 20 µg vaccinations with JEV/GETV vaccine or PBS, antibody measurements and RRVTT challenge; (f) GETV and RRVTT endpoint IgG ELISA titers after 2 vaccinations with JEV/GETV or PBS (limit of detection 1 in 30); (g) GETVMM2021 and RRVTT 50% neutralization titers after 2 vaccinations with JEV/GETV vaccine or PBS (limit of detection 1 in 10); (h) RRVTT viremia post-challenge with RRVTT in mice vaccinated twice with JEV/GETV vaccine or PBS (n = 6 mice per group). Statistics by Kolmogorov-Smirnov tests; (i) As for Figure 3a,b the 48 E1/E2-MXRA8 contact residues (based on CHIKV) are aligned for RRVTT and GETVMI-110 (GETV1, vaccine strain) and GETVMM2021 (GETV2) E1/E2, with GETVMI-110 residues colored in the cryo-EM structures of E1/E2. GETVMI-110 shows 75% amino acid identity in these 48 amino acids with RRVTT. The conserved, but formalin-fixation-sensitive, amino acids K and W are underlined.

Figure 6. Cross-protection against RRVTT mediated by SCV-ZIKA/CHIK vaccinations in adult IRF3/7-/- mice. (a) Timeline of vaccination with a single dose of 106 pfu SCV-ZIKA/CHIK or SCV-Control, antibody measurements and RRVTT challenge in adult IRF3/7-/- mice; (b) CHIKV and RRVTT endpoint IgG ELISA titers after vaccination with SCV-ZIKA/CHIK or SCV-Control (limit of detection 1 in 30); (c) CHIKV and RRVTT 50% neutralization titers after vaccination with SCV-ZIKA/CHIK or SCV-Control (limit of detection 1 in 10); (d) Mean viremias post-challenge with RRVTT (n = 6 mice per group). mice were euthanized. Statistics by t-tests; (e) Mean percentage increase in foot swelling (height x width) relative to day 0 for each foot (n = 12 feet from 6 mice per group); (f) Pictures showing examples of feet on day 0 and day 6 post-infection, illustrating swelling on day 6 in the control group; (g) Mice were scored for 1 = mild, 2 = moderate, 3 = severe for the indicated 6 disease manifestations. The mean scores for each disease manifestation for 6 mice per group are shown for SCV-ZIKA/CHIK (left) and SCV-Control vaccinated mice (right); (h) Kaplan-Meier survival curves for mice described in (g), with mice scoring 2 or more for two disease manifestations deemed to have reached ethically defined endpoints requiring euthanasia. An additional group (n = 3) were mock-vaccinated with PBS. Statistics by log rank test.

Figure 7. Antibody-mediated cross-protection in Rag-/- mice. (a) Timeline of infections, viremia determinations and injection of convalescent CHIKV mouse serum in Rag1-/- mice; (b) Viremias for the indicated alphaviruses before and after injection of anti-CHIKV convalescent serum (n = 4 mice per group). (Limit of detection for each mouse 2 log10CCID50/mL.) For all reductions to undetectable viremia levels for each day relative to day 10, p = 0.037 by Kolmogorov-Smirnov tests (as differences in variance were infinite).

Supplementary Materials

The following are available online at https://www.mdpi.com/2076-393X/8/2/209/s1, Figure S1: Injection of alphaviruses into hind feet, Figure S2: Growth of alphavirus stocks after infection at MOI ≈ 0.01, Figure S3: Comparisons between RRVTT and RRVT48, Figure S4: Individual mouse data for Figure 2, Figure S5: Protection against RRVTT with different doses/schedules of SCV-ZIKA/CHIK vaccination, Figure S6: RRV infection of IRF3/7-/-mice, Figure S7: Virus reappearance in Rag1-/- mice correlates with E1/E2 identity, Figure S8: Statistical comparisons of neutralizing and ELISA antibodies, Figure S9: Anti-RRVTT activity of IgM and ribavirin.

Author Contributions

Conceptualization, P.M.H. and A.S.; data curation, A.S.; formal analysis, D.W., R.J.N.A., G.H. and A.S.; funding acquisition, P.Y., N.A.P. and A.S.; investigation, W.N., E.N., K.Y., B.T., T.T.L. and D.J.R.; resources, L.L., T.H.C., J.D.H., H.M.F., J.H.-P., R.A.H., N.M.O. and P.M.H.; supervision, N.A.P. and A.S.; writing-review and editing, D.J.R. and V.P.L. All authors have read and agreed to the published version of the manuscript.

Funding

W.N. was awarded a Research Training Program (Tuition fee offset and Living allowance stipend) Ph.D. Scholarship from the Faculty of Medicine, University of Queensland, Australia. The work was also supported by a project grant from the National Health and Medical Research Council (NHMRC) of Australia (APP1078468), intramural seed funding from the Australian Infectious Disease Research Centre, and an Advance Queensland Research Fellowship awarded to N.A.P. by the Queensland Government, Australia, with co-funding from Sementis. A.S. is a Leadership Fellowship with the National Health and Medical Research Council of Australia. E.N. was supported in part by the Daiichi Sankyo Foundation of Life Science. H.M.F. Australian governments fund the Australian Red Cross Blood Service for the provision of blood, blood products and services to the Australian community.

Acknowledgments

We thank the QIMR B animal house staff for their assistance, Clay Winterford (QIMR B) and his team for their help with histology and immunohistochemistry, and Gunter Hartel (QIMR B) for help with statistics. We thank I Anraku for his assistance in managing the BSL3 facility at QIMR B. We thank G. Pijlman (University of Wageningen, Holland) for providing ONNV and MAYV. We thank C. K. Lim (NIID, Tokyo, Japan) for help with import of the JEV/GETV vaccine and G Burgess (James Cook University, Qld., Australia) for provision of monoclonal antibodies. We also thank Sementis for supply of the SCV vaccines.

Conflicts of Interest

A.S. was an unpaid Scientific Advisory Board member of Sementis (2011-2019) and was an occasional paid consultant for Sementis (2019). PMH was until April 2020 the CEO/CSO of Sementis. J.D.H.'s research group conducts collaborative research with Sementis, financially supported, in whole or in part, by Sementis. L.L, T.H.C. and N.A.P. have had, and/or currently have, salary and/or project support from funds provided, in whole or in part, by Sementis. L.L., T.H.C., J.D.H., A.S. and N.A.P. own Sementis shares. Sementis had no influence on the interpretation or presentation of the data.

1. Pezzi, L.; Rodriguez-Morales, A.J.; Reusken, C.B.; Ribeiro, G.S.; LaBeaud, A.D.; Lourenco-de-Oliveira, R.; Brasil, P.; Lecuit, M.; Failloux, A.B.; Gallian, P.; et al. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus. Antivir. Res. 2019, 172, 104610.

2. Pezzi, L.; LaBeaud, A.D.; Reusken, C.B.; Drexler, J.F.; Vasilakis, N.; Diallo, M.; Simon, F.; Jaenisch, T.; Gallian, P.; Sall, A.; et al. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o'nyong-nyong virus. Antivir. Res. 2019, 172, 104611.

3. Harley, D.; Suhrbier, A. Ross River Virus Disease. In Hunter's Tropical Medicine and Emerging Infectious Diseases, 10th ed.; Ryan, E.T., Hill, D.R., Solomon, T., Eds.; Elsevier Health Sciences: Amsterdam, the Netherlands, 2019; Volume 3, pp. 342-344.

4. Suhrbier, A.; Jaffar-Bandjee, M.C.; Gasque, P. Arthritogenic alphaviruses-an overview. Nat. Rev. Rheumatol. 2012, 8, 420-429.

5. Suhrbier, A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. Nat. Rev. Rheumatol. 2019, 15, 597-611.

6. Powers, A.M. Risks to the Americas associated with the continued expansion of chikungunya virus. J. Gen. Virol. 2015, 96, 1-5.

7. Farmer, J.F.; Suhrbier, A. Interpreting paired serology for Ross River virus and Barmah Forest virus diseases. Aust. J. Gen. Pract. 2019, 48, 645-649.

8. Harley, D.; Sleigh, A.; Ritchie, S. Ross River virus transmission, infection, and disease: A cross-disciplinary review. Clin. Microbiol. Rev. 2001, 14, 909-932.

9. Liu, W.; Kizu, J.R.; Le Grand, L.R.; Moller, C.G.; Carthew, T.L.; Mitchell, I.R.; Gubala, A.J.; Aaskov, J.G. Localized Outbreaks of Epidemic Polyarthritis among Military Personnel Caused by Different Sublineages of Ross River Virus, Northeastern Australia, 2016-2017. Emerg. Infect. Dis. 2019, 25, 1793-1801.

10. Shanks, G.D. Could Ross River Virus Be the Next Zika? J. Travel. Med. 2019, 26, taz003.

11. Lanciotti, R.S.; Ludwig, M.L.; Rwaguma, E.B.; Lutwama, J.J.; Kram, T.M.; Karabatsos, N.; Cropp, B.C.; Miller, B.R. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence: Genetic characterization of the virus. Virology 1998, 252, 258-268.

12. Rezza, G.; Chen, R.; Weaver, S.C. O'nyong-nyong fever: A neglected mosquito-borne viral disease. Pathog. Global Health 2017, 111, 271-275.

13. Pezzi, L.; Reusken, C.B.; Weaver, S.C.; Drexler, J.F.; Busch, M.; LaBeaud, A.D.; Diamond, M.S.; Vasilakis, N.; Drebot, M.A.; Siqueira, A.M.; et al. GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics. Antivir. Res. 2019, 166, 66-81.

14. Acosta-Ampudia, Y.; Monsalve, D.M.; Rodriguez, Y.; Pacheco, Y.; Anaya, J.M.; Ramirez-Santana, C. Mayaro: An emerging viral threat? Emerg. Microbes Infect. 2018, 7, 163.

15. Mavian, C.; Rife, B.D.; Dollar, J.J.; Cella, E.; Ciccozzi, M.; Prosperi, M.C.F.; Lednicky, J.; Morris, J.G.; Capua, I.; Salemi, M. Emergence of recombinant Mayaro virus strains from the Amazon basin. Sci. Rep. 2017, 7, 8718.

16. Prow, N.A.; Liu, L.; Nakayama, E.; Cooper, T.H.; Yan, K.; Eldi, P.; Hazlewood, J.E.; Tang, B.; Le, T.T.; Setoh, Y.X.; et al. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nat. Commun. 2018, 9, 1230.

17. DeFilippis, V.R. Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. Curr. Top. Microbiol. Immunol. 2019, 364, 1-26.

18. Reisinger, E.C.; Tschismarov, R.; Beubler, E.; Wiedermann, U.; Firbas, C.; Loebermann, M.; Pfeiffer, A.; Muellner, M.; Tauber, E.; Ramsauer, K. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 2019, 392, 2718-2727.

19. Roques, P.; Ljungberg, K.; Kummerer, B.M.; Gosse, L.; Dereuddre-Bosquet, N.; Tchitchek, N.; Hallengard, D.; Garcia-Arriaza, J.; Meinke, A.; Esteban, M.; et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2017, 2, e83527.

20. Rezza, G.; Weaver, S.C. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. PLoS Neglected Trop. Dis. 2019, 13, e0006919.

21. Powers, A.M. Licensed chikungunya virus vaccine: A possibility? Lancet 2019, 392, 2660-2661.

22. Wressnigg, N.; van der Velden, M.V.; Portsmouth, D.; Draxler, W.; O'Rourke, M.; Richmond, P.; Hall, S.; McBride, W.J.; Redfern, A.; Aaskov, J.; et al. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clin. Vaccine Immunol. 2015, 22, 267-273.

23. Metz, S.W.; Gardner, J.; Geertsema, C.; Le, T.T.; Goh, L.; Vlak, J.M.; Suhrbier, A.; Pijlman, G.P. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Neglected Trop. Dis. 2013, 7, e2124.

24. Wang, D.; Suhrbier, A.; Penn-Nicholson, A.; Woraratanadharm, J.; Gardner, J.; Luo, M.; Le, T.T.; Anraku, I.; Sakalian, M.; Einfeld, D.; et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011, 29, 2803-2809.

25. Weger-Lucarelli, J.; Aliota, M.T.; Kamlangdee, A.; Osorio, J.E. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. PLoS Neglected Trop. Dis. 2015, 9, e0004163.

26. Yap, M.L.; Klose, T.; Urakami, A.; Hasan, S.S.; Akahata, W.; Rossmann, M.G. Structural studies of Chikungunya virus maturation. Proc. Natl. Acad. Sci. USA 2017, 114, 13703-13707.

27. Jin, J.; Liss, N.M.; Chen, D.H.; Liao, M.; Fox, J.M.; Shimak, R.M.; Fong, R.H.; Chafets, D.; Bakkour, S.; Keating, S.; et al. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Rep. 2015, 13, 2553-2564.

28. Eldi, P.; Cooper, T.H.; Liu, L.; Prow, N.A.; Diener, K.R.; Howley, P.M.; Suhrbier, A.; Hayball, J.D. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology. Mol. Ther. 2017, 25, 2332-2344.

29. Prow, N.A.; Liu, L. The vaccinia-virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. npj Vaccines, accepted.

30. Gouglas, D.; Thanh Le, T.; Henderson, K.; Kaloudis, A.; Danielsen, T.; Hammersland, N.C.; Robinson, J.M.; Heaton, P.M.; Rottingen, J.A. Estimating the cost of vaccine development against epidemic infectious diseases: A cost minimisation study. Lancet Glob. Health 2018, 6, e1386-e1396.

31. Bannai, H.; Nemoto, M.; Ochi, A.; Kikuchi, T.; Kobayashi, M.; Tsujimura, K.; Yamanaka, T.; Kondo, T. Epizootiological Investigation of Getah Virus Infection among Racehorses in Japan in 2014. J. Clin. Microbiol. 2015, 53, 2286-2291.

32. Bannai, H.; Ochi, A.; Nemoto, M.; Tsujimura, K.; Yamanaka, T.; Kondo, T. A 2015 outbreak of Getah virus infection occurring among Japanese racehorses sequentially to an outbreak in 2014 at the same site. BMC Vet. Res. 2016, 12, 98.

33. Nemoto, M.; Bannai, H.; Tsujimura, K.; Kobayashi, M.; Kikuchi, T.; Yamanaka, T.; Kondo, T. Getah Virus Infection among Racehorses, Japan, 2014. Emerg. Infect. Dis. 2015, 21, 883-885.

34. Fukunaga, Y.; Kumanomido, T.; Kamada, M. Getah virus as an equine pathogen. Vet. Clin. North Am. Large Anim. Pract. 2000, 16, 605-617.

35. Lu, G.; Ou, J.; Ji, J.; Ren, Z.; Hu, X.; Wang, C.; Li, S. Emergence of Getah Virus Infection in Horse With Fever in China, 2018. Front. Microbiol. 2019, 10, 1416.

36. Liu, H.; Zhang, X.; Li, L.X.; Shi, N.; Sun, X.T.; Liu, Q.; Jin, N.Y.; Si, X.K. First isolation and characterization of Getah virus from cattle in northeastern China. BMC Vet. Res. 2019, 15, 320.

37. Gummow, B.; Tan, R.; Joice, R.K.; Burgess, G.; Picard, J. Seroprevalence and associated risk factors of mosquito-borne alphaviruses in horses in northern Queensland. Aust. Vet. J. 2018, 96, 243-251.

38. Stephenson, E.B.; Peel, A.J.; Reid, S.A.; Jansen, C.C.; McCallum, H. The non-human reservoirs of Ross River virus: A systematic review of the evidence. Parasites Vectors 2018, 11, 188.

39. El-Hage, C.M.; McCluskey, M.J.; Azuolas, J.K. Disease suspected to be caused by Ross River virus infection of horses. Aust. Vet. J. 2008, 86, 367-370.

40. Barton, A.; Bielefeldt-Ohmann, H. Clinical Presentation, Progression, and Management of Five Cases of Ross River Virus Infection in Performance Horses Located in Southeast Queensland: A Longitudinal Case Series. J. Equine Vet. Sci. 2017, 51, 34-40.

41. Calisher, C.H.; Shope, R.E.; Brandt, W.; Casals, J.; Karabatsos, N.; Murphy, F.A.; Tesh, R.B.; Wiebe, M.E. Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus. Intervirology 1980, 14, 229-232.

42. Gardner, J.; Anraku, I.; Le, T.T.; Larcher, T.; Major, L.; Roques, P.; Schroder, W.A.; Higgs, S.; Suhrbier, A. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 2010, 84, 8021-8032.

43. Martins, K.A.; Gregory, M.K.; Valdez, S.M.; Sprague, T.R.; Encinales, L.; Pacheco, N.; Cure, C.; Porras-Ramirez, A.; Rico-Mendoza, A.; Chang, A.; et al. Neutralizing Antibodies from Convalescent Chikungunya Virus Patients Can Cross-Neutralize Mayaro and Una Viruses. Am. J. Trop. Med. Hyg. 2019, 100, 1541-1544.

44. Webb, E.M.; Azar, S.R.; Haller, S.L.; Langsjoen, R.M.; Cuthbert, C.E.; Ramjag, A.T.; Luo, H.; Plante, K.; Wang, T.; Simmons, G.; et al. Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential. Sci. Rep. 2019, 9, 20399.

45. Fox, J.M.; Long, F.; Edeling, M.A.; Lin, H.; van Duijl-Richter, M.K.S.; Fong, R.H.; Kahle, K.M.; Smit, J.M.; Jin, J.; Simmons, G.; et al. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell 2015, 163, 1095-1107.

46. Earnest, J.T.; Basore, K.; Roy, V.; Bailey, A.L.; Wang, D.; Alter, G.; Fremont, D.H.; Diamond, M.S. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. J. Exp. Med. 2019, 216, 2282-2301.

47. Partidos, C.D.; Paykel, J.; Weger, J.; Borland, E.M.; Powers, A.M.; Seymour, R.; Weaver, S.C.; Stinchcomb, D.T.; Osorio, J.E. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 2012, 30, 4638-4643.

48. Holzer, G.W.; Coulibaly, S.; Aichinger, G.; Savidis-Dacho, H.; Mayrhofer, J.; Brunner, S.; Schmid, K.; Kistner, O.; Aaskov, J.G.; Falkner, F.G.; et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 2011, 29, 4132-4141.

49. Fine, D.L.; Allen, W.P.; Wilkins, L.B. Features of cross protection between Sindbis and Venezuelan equine encephalitis viruses in mice--relationship of route of immunization to protection. J. Gen. Virol. 1974, 24, 401-408.

50. Wust, C.J.; Crombie, R.; Brown, A. Passive protection across subgroups of alphaviruses by hyperimmune non-cross-neutralizing anti-Sindbis serum. Proc. Soc. Exp. Biol. Med. 1987, 184, 56-63.

51. Peck, R.; Wust, C.J.; Brown, A. Adoptive transfer of cross-protection among alphaviruses in mice requires allogeneic stimulation. Infect. Immun. 1979, 25, 320-327.

52. Langsjoen, R.M.; Haller, S.L.; Roy, C.J.; Vinet-Oliphant, H.; Bergren, N.A.; Erasmus, J.H.; Livengood, J.A.; Powell, T.D.; Weaver, S.C.; Rossi, S.L. Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models. MBio 2018, 9, e02449-17.

53. Hoad, V.C.; Speers, D.J.; Keller, A.J.; Dowse, G.K.; Seed, C.R.; Lindsay, M.D.; Faddy, H.M.; Pink, J. First reported case of transfusion-transmitted Ross River virus infection. Med. J. Aust. 2015, 202, 267-270.

54. Prow, N.A.; Jimenez Martinez, R.; Hayball, J.D.; Howley, P.M.; Suhrbier, A. Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert. Rev. Vaccines 2018, 17, 925-934.

55. Rudd, P.A.; Wilson, J.; Gardner, J.; Larcher, T.; Babarit, C.; Le, T.T.; Anraku, I.; Kumagai, Y.; Loo, Y.M.; Gale, M., Jr.; et al. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J. Virol. 2012, 86, 9888-9898.

56. Poo, Y.S.; Rudd, P.A.; Gardner, J.; Wilson, J.A.; Larcher, T.; Colle, M.A.; Le, T.T.; Nakaya, H.I.; Warrilow, D.; Allcock, R.; et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Neglected Trop. Dis. 2014, 8, e3354.

57. Wilson, J.A.; Prow, N.A.; Schroder, W.A.; Ellis, J.J.; Cumming, H.E.; Gearing, L.J.; Poo, Y.S.; Taylor, A.; Hertzog, P.J.; Di Giallonardo, F.; et al. RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation. PLoS Pathog. 2017, 13, e1006155.

58. Johnson, B.J.; Le, T.T.; Dobbin, C.A.; Banovic, T.; Howard, C.B.; Flores Fde, M.; Vanags, D.; Naylor, D.J.; Hill, G.R.; Suhrbier, A. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J. Biol. Chem. 2005, 280, 4037-4047.

59. Doherty, R.L.; Carley, J.G.; Mackerras, M.J.; Marks, E.N. Studies of arthropod-borne virus infections in Queensland. III. Isolation and characterization of virus strains from wild-caught mosquitoes in North Queensland. Aust. J. Exp. Biol. Med. Sci. 1963, 41, 17-39.

60. Taylor, W.P.; Marshall, I.D. Adaptation studies with Ross River virus: Laboratory mice and cell cultures. J. Gen. Virol. 1975, 28, 59-72.

61. Parola, P.; de Lamballerie, X.; Jourdan, J.; Rovery, C.; Vaillant, V.; Minodier, P.; Brouqui, P.; Flahault, A.; Raoult, D.; Charrel, R.N. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg. Infect. Dis. 2006, 12, 1493-1499.

62. Bessaud, M.; Peyrefitte, C.N.; Pastorino, B.A.; Gravier, P.; Tock, F.; Boete, F.; Tolou, H.J.; Grandadam, M. O'nyong-nyong Virus, Chad. Emerg. Infect. Dis. 2006, 12, 1248-1250.

63. Varghese, F.S.; Thaa, B.; Amrun, S.N.; Simarmata, D.; Rausalu, K.; Nyman, T.A.; Merits, A.; McInerney, G.M.; Ng, L.F.P.; Ahola, T. The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. J. Virol. 2016, 90, 9743-9757.

64. Pinheiro, F.P.; Freitas, R.B.; Travassos da Rosa, J.F.; Gabbay, Y.B.; Mello, W.A.; LeDuc, J.W. An outbreak of Mayaro virus disease in Belterra, Brazil. I. Clinical and virological findings. Am. J. Trop. Med. Hyg. 1981, 30, 674-681.

65. La Linn, M.; Bellett, A.J.; Parsons, P.G.; Suhrbier, A. Complete removal of mycoplasma from viral preparations using solvent extraction. J. Virol. Methods 1995, 52, 51-54.

66. Warrilow, D.; Hall-Mendelin, S.; Hobson-Peters, J.; Prow, N.A.; Allcock, R.; Hall, R.A. Complete coding sequences of three members of the kokobera group of flaviviruses. Genome Announc. 2014, 2, e00890-14.

67. Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol. Biol. Evol. 2016, 33, 1870-1874.

68. Faddy, H.M.; Tran, T.V.; Hoad, V.C.; Seed, C.R.; Viennet, E.; Chan, H.T.; Harley, R.; Hewlett, E.; Hall, R.A.; Bielefeldt-Ohmann, H.; et al. Ross River virus in Australian blood donors: Possible implications for blood transfusion safety. Transfusion 2018, 58, 485-492.

69. Schroder, W.A.; Le, T.T.; Major, L.; Street, S.; Gardner, J.; Lambley, E.; Markey, K.; MacDonald, K.P.; Fish, R.J.; Thomas, R.; et al. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. J. Immunol. 2010, 184, 2663-2670.

70. Poo, Y.S.; Nakaya, H.; Gardner, J.; Larcher, T.; Schroder, W.A.; Le, T.T.; Major, L.D.; Suhrbier, A. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis. J. Virol. 2014, 88, 6862-6872.

71. Zouache, K.; Fontaine, A.; Vega-Rua, A.; Mousson, L.; Thiberge, J.M.; Lourenco-De-Oliveira, R.; Caro, V.; Lambrechts, L.; Failloux, A.B. Three-way interactions between mosquito population, viral strain and temperature underlying chikungunya virus transmission potential. Proc. Biol. Sci. 2014, 281, 20141078.

72. Song, H.; Zhao, Z.; Chai, Y.; Jin, X.; Li, C.; Yuan, F.; Liu, S.; Gao, Z.; Wang, H.; Song, J.; et al. Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein. Cell 2019, 177, 1714-1724.

73. Oliveira, N.M. Analysis of Ross River virus using monoclonal and polyclonal antibodies with applications in diagnostic and surveillance techniques. Ph.D. Thesis, University of Western Australia, Crawley, Australia, 1998.

74. O'Brien, C.A.; Hobson-Peters, J.; Yam, A.W.; Colmant, A.M.; McLean, B.J.; Prow, N.A.; Watterson, D.; Hall-Mendelin, S.; Warrilow, D.; Ng, M.L.; et al. Viral RNA intermediates as targets for detection and discovery of novel and emerging mosquito-borne viruses. PLoS Neglected Trop. Dis. 2015, 9, e0003629.

75. Prow, N.A.; Tang, B.; Gardner, J.; Le, T.T.; Taylor, A.; Poo, Y.S.; Nakayama, E.; Hirata, T.D.C.; Nakaya, H.I.; Slonchak, A.; et al. Lower temperatures reduce type I interferon activity and promote alphaviral arthritis. PLoS Pathog. 2017, 13, e1006788.

76. Wolf, S.; Taylor, A.; Zaid, A.; Freitas, J.; Herrero, L.J.; Rao, S.; Suhrbier, A.; Forwood, M.R.; Bucala, R.; Mahalingam, S. Inhibition of Interleukin-1beta Signaling by Anakinra Demonstrates a Critical Role of Bone Loss in Experimental Arthritogenic Alphavirus Infections. Arthritis Rheumatol. 2019, 71, 1185-1190.

77. Chen, W.; Foo, S.S.; Zaid, A.; Teng, T.S.; Herrero, L.J.; Wolf, S.; Tharmarajah, K.; Vu, L.D.; van Vreden, C.; Taylor, A.; et al. Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nat. Microbiol. 2017, 2, 1435-1445.

78. Seay, A.R.; Griffin, D.E.; Johnson, R.T. Experimental viral polymyositis: Age dependency and immune responses to Ross River virus infection in mice. Neurology 1981, 31, 656-660.

79. Rulli, N.E.; Guglielmotti, A.; Mangano, G.; Rolph, M.S.; Apicella, C.; Zaid, A.; Suhrbier, A.; Mahalingam, S. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheumatol. 2009, 60, 2513-2523.

80. Herrero, L.; Nelson, M.; Bettadapura, J.; Gahan, M.E.; Mahalingam, S. Applications of animal models of infectious arthritis in drug discovery: A focus on alphaviral disease. Curr. Drug Targets 2011, 12, 1024-1036.

81. Jin, J.; Simmons, G. Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. Viruses 2019, 11, 305.

82. Burrack, K.S.; Montgomery, S.A.; Homann, D.; Morrison, T.E. CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice. J. Immunol. 2015, 194, 678-689.

83. Chanas, A.C.; Hubalek, Z.; Johnson, B.K.; Simpson, D.I. A comparative study of O'nyong nyong virus with Chikungunya virus and plaque variants. Arch. Virol. 1979, 59, 231-238.

84. La Linn, M.; Gardner, J.; Warrilow, D.; Darnell, G.A.; McMahon, C.R.; Field, I.; Hyatt, A.D.; Slade, R.W.; Suhrbier, A. Arbovirus of marine mammals: A new alphavirus isolated from the elephant seal louse, Lepidophthirus macrorhini. J. Virol. 2001, 75, 4103-4109.

85. Fox, J.M.; Diamond, M.S. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus. J. Immunol. 2016, 197, 4210-4218.

86. Miyata, T.; Miyazawa, S.; Yasunaga, T. Two types of amino acid substitutions in protein evolution. J. Mol. Evol. 1979, 12, 219-236.

87. Quintel, B.K.; Thomas, A.; Poer DeRaad, D.E.; Slifka, M.K.; Amanna, I.J. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Vaccine 2019, 37, 4214-4221.

88. Fan, Y.C.; Chiu, H.C.; Chen, L.K.; Chang, G.J.; Chiou, S.S. Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Neglected Trop. Dis. 2015, 9, e0004167.

89. Vani, K.; Bogen, S.A.; Sompuram, S.R. A high throughput combinatorial library technique for identifying formalin-sensitive epitopes. J. Immunol. Methods 2006, 317, 80-89.

90. Zhang, Y.N.; Deng, C.L.; Li, J.Q.; Li, N.; Zhang, Q.Y.; Ye, H.Q.; Yuan, Z.M.; Zhang, B. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: A New Approach for a CHIKV Vaccine. J. Virol. 2019, 93, e00504-19.

91. Brandler, S.; Ruffie, C.; Combredet, C.; Brault, J.B.; Najburg, V.; Prevost, M.C.; Habel, A.; Tauber, E.; Despres, P.; Tangy, F. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013, 31, 3718-3725.

92. Akahata, W.; Yang, Z.Y.; Andersen, H.; Sun, S.; Holdaway, H.A.; Kong, W.P.; Lewis, M.G.; Higgs, S.; Rossmann, M.G.; Rao, S.; et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 2010, 16, 334-338.

93. Gardner, J.; Rudd, P.A.; Prow, N.A.; Belarbi, E.; Roques, P.; Larcher, T.; Gresh, L.; Balmaseda, A.; Harris, E.; Schroder, W.A.; et al. Infectious Chikungunya Virus in the Saliva of Mice, Monkeys and Humans. PLoS ONE 2015, 10, e0139481.

94. Smith-Owirodu, A.; Wust, C.J.; Gates, D.; Brown, A. Cross-protection correlates with delayed antibody formation to challenge virus after immunization with Sindbis virus. J. Gen. Virol. 1980, 51, 351-357.

95. Peck, R.D.; Brown, A.; Wust, C.J. Preliminary evidence for cell-mediated immunity in cross-protection among group A arboviruses. J. Immunol. 1975, 114, 581-584.

96. Wolcott, J.A.; Wust, C.J.; Brown, A. Cross-reactive target antigen in cell-mediated cytolysis of cells infected with a temperature-sensitive mutant of Sindbis virus. J. Gen. Virol. 1985, 66, 1167-1170.

97. Latif, Z.; Gates, D.; Wust, C.J.; Brown, A. Cross protection among togaviruses in nude mice and littermates. J. Gen. Virol. 1979, 45, 89-98.

98. Mullbacher, A.; Marshall, I.D.; Blanden, R.V. Cross-reactive cytotoxic T cells to alphavirus infection. Scand. J. Immunol. 1979, 10, 291-296.

99. Wust, C.J.; Nicholas, J.A.; Fredin, D.; Dodd, D.C.; Brideau, R.J.; Levely, M.E.; Brown, A. Monoclonal antibodies that cross-react with the E1 glycoprotein of different alphavirus serogroups: Characterization including passive protection in vivo. Virus Res. 1989, 13, 101-112.

100. Herve, C.; Laupeze, B.; Del Giudice, G.; Didierlaurent, A.M.; Da Silva, F.T. The how's and what's of vaccine reactogenicity. npj Vaccines 2019, 4, 39.

101. Yoon, I.K.; Alera, M.T.; Lago, C.B.; Tac-An, I.A.; Villa, D.; Fernandez, S.; Thaisomboonsuk, B.; Klungthong, C.; Levy, J.W.; Velasco, J.M.; et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Neglected Trop. Dis. 2015, 9, e0003764.

102. Milligan, G.N.; Schnierle, B.S.; McAuley, A.J.; Beasley, D.W.C. Defining a correlate of protection for chikungunya virus vaccines. Vaccine 2019, 37, 7427-7436.

103. Rudd, P.A.; Raphael, A.P.; Yamada, M.; Nufer, K.L.; Gardner, J.; Le, T.T.; Prow, N.A.; Dang, N.; Schroder, W.A.; Prow, T.W.; et al. Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm. Vaccine 2015, 33, 5172-5180.

104. de Castro-Jorge, L.A.; de Carvalho, R.V.H.; Klein, T.M.; Hiroki, C.H.; Lopes, A.H.; Guimaraes, R.M.; Fumagalli, M.J.; Floriano, V.G.; Agostinho, M.R.; Slhessarenko, R.D.; et al. The NLRP3 inflammasome is involved with the pathogenesis of Mayaro virus. PLoS Pathog. 2019, 15, e1007934.

105. Michlmayr, D.; Pak, T.R.; Rahman, A.H.; Amir, E.D.; Kim, E.Y.; Kim-Schulze, S.; Suprun, M.; Stewart, M.G.; Thomas, G.P.; Balmaseda, A.; et al. Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. Mol. Syst. Biol. 2018, 14, e7862.

106. Soares-Schanoski, A.; Baptista Cruz, N.; de Castro-Jorge, L.A.; de Carvalho, R.V.H.; Santos, C.A.D.; Ros, N.D.; Oliveira, U.; Costa, D.D.; Santos, C.; Cunha, M.D.P.; et al. Systems analysis of subjects acutely infected with the Chikungunya virus. PLoS Pathog. 2019, 15, e1007880.

107. Hu, W.G.; Steigerwald, R.; Kalla, M.; Volkmann, A.; Noll, D.; Nagata, L.P. Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine 2018, 36, 5194-5203.

108. Devine, G.J.; Overgaard, H.J.; Paul, R.E. Global Vector Control Guidelines-The Need For Co-Creation. Trends Parasitol. 2019, 35, 267-270.

Wilson Nguyen1, Eri Nakayama1,2, Kexin Yan1, Bing Tang1, Thuy T. Le1, Liang Liu3, Tamara H. Cooper3, John D. Hayball3, Helen M. Faddy4, David Warrilow5, Richard J. N. Allcock6, Jody Hobson-Peters7, Roy A. Hall7,8, Daniel J. Rawle1, Viviana P. Lutzky1, Paul Young7,8, Nidia M. Oliveira9, Gunter Hartel10, Paul M. Howley11, Natalie A. Prow1,3,8,* and Andreas Suhrbier1,8,*

1Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia

2Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-0052, Japan

3Experimental Therapeutics Laboratory, School of Pharmacy & Medical Sciences, University of South Australia Cancer Research Institute, SA 5000, Australia

4Research and Development Laboratory, Australian Red Cross Lifeblood, Kelvin Grove, Qld 4059, Australia

5Public Health Virology Laboratory, Queensland Health Forensic and Scientific Services, PO Box 594, Archerfield, Qld 4108, Australia

6School of Biomedical Sciences, University of Western Australia, Crawley 6009, Australia

7School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Qld 4072, Australia

8Australian Infectious Disease Research Centre, Brisbane, Qld 4027 & 4072, Australia

9Deptartment of Microbiology, University of Western Australia, Perth, WA 6009, Australia

10Statistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Qld 4029, Australia

11Sementis Ltd., Berwick, VIC 3806, Australia

*Authors to whom correspondence should be addressed.

Word count: 12459

Show less

© 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Chikungunya virus (CHIKV), Ross River virus (RRV), o’nyong nyong virus (ONNV), Mayaro virus (MAYV) and Getah virus (GETV) represent arthritogenic alphaviruses belonging to the Semliki Forest virus antigenic complex. Antibodies raised against one of these viruses can cross-react with other serogroup members, suggesting that, for instance, a CHIKV vaccine (deemed commercially viable) might provide cross-protection against antigenically related alphaviruses. Herein we use human alphavirus isolates (including a new human RRV isolate) and wild-type mice to explore whether infection with one virus leads to cross-protection against viremia after challenge with other members of the antigenic complex. Persistently infected Rag1-/- mice were also used to assess the cross-protective capacity of convalescent CHIKV serum. We also assessed the ability of a recombinant poxvirus-based CHIKV vaccine and a commercially available formalin-fixed, whole-virus GETV vaccine to induce cross-protective responses. Although cross-protection and/or cross-reactivity were clearly evident, they were not universal and were often suboptimal. Even for the more closely related viruses (e.g., CHIKV and ONNV, or RRV and GETV), vaccine-mediated neutralization and/or protection against the intended homologous target was significantly more effective than cross-neutralization and/or cross-protection against the heterologous virus. Effective vaccine-mediated cross-protection would thus likely require a higher dose and/or more vaccinations, which is likely to be unattractive to regulators and vaccine manufacturers.

Details

Title
Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models
Author
Wilson, Nguyen  VIAFID ORCID Logo  ; Nakayama, Eri  VIAFID ORCID Logo  ; Yan, Kexin; Tang, Bing; Le, Thuy T; Liu, Liang; Cooper, Tamara H; Hayball, John D; Faddy, Helen M; Warrilow, David  VIAFID ORCID Logo  ; Allcock, Richard J N; Hobson-Peters, Jody  VIAFID ORCID Logo  ; Hall, Roy A; Rawle, Daniel J  VIAFID ORCID Logo  ; Lutzky, Viviana P; Young, Paul; Oliveira, Nidia M; Hartel, Gunter  VIAFID ORCID Logo  ; Howley, Paul M; Prow, Natalie A; Suhrbier, Andreas  VIAFID ORCID Logo 
First page
209
Publication year
2020
Publication date
2020
Publisher
MDPI AG
e-ISSN
2076393X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.3390/vaccines8020209
ProQuest document ID
2400155388
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.